Drug
Igiv C 10
Igiv C 10: highest development phase Phase 3, developed by Grifols. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Grifols
Trials
| Drug | Phase | Indication |
|---|---|---|
| IGIV-C 10% NCT02604810 | Phase 3 | Primary Immunodeficiency |
Latest
No recent events.
Follow Igiv C 10 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.